FibroBiologics CSO invests $500,000 in private placement

FibroBiologics Inc., a clinical-stage biotechnology company, recently completed a private placement with its Chief Scientific Officer Hamid Khoja, raising approximately $500,000 in gross proceeds. The transaction saw Khoja purchase 298,508 shares of common stock and the corresponding warrants to buy up to 298,508 additional shares at a price of $1.675 each, including $1.55 per share and $0.125 per warrant.

The shares were priced at the Nasdaq Capital Market's closing bid on September 14, 2026. The warrants, exercisable immediately, have an expiration date of five years from issuance. FibroBiologics plans to utilize the net proceeds for general corporate purposes and working capital. Khoja, hailed as the "scientific architect of our platform," stated that his increased investment demonstrates his commitment to the company's scientific endeavors, team, and therapeutic development for patient benefit.